Add Presentation to Slide Tray Presentation:
First- and Second-Generation Antipsychotics for Children and Young Adults
Authors: John H. Coverdale, MD, MEd
Gaps in Knowledge (2 of 2)
- Evidence about efficacy and safety over several years is unavailable.
- Standardized scales and methods for systematically investigating adverse events are needed.
- How the characteristics of key patient subpopulations affect patient-centered outcomes is not understood.
- Large-scale effectiveness studies that apply few patient restrictions and closely match typical clinical practice are needed to inform clinical decisionmaking.
- Seida J, Schouten J, Mousavi S, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Comparative Effectiveness Review No. 39 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 11(12)-EHC077-EF. Available at www.effectivehealthcare.ahrq.gov/pedantipsych.cfm.
Your slide tray is being processed.